{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:49:29Z","timestamp":1789602569098,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Research and Development & Development, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible patients had SMM and relevant measures to apply Mayo 2018, International Myeloma Working Group (IMWG) 2020, and AQUILA trial risk criteria. Time to progression to active MM (TTP), progression or death (PFS), and death or progression on first-line MM therapy (PFS2) were evaluated using Kaplan\u2013Meier methods and multivariate Cox regression models adjusted for age, Charlson Comorbidity Index, and time from SMM diagnosis to risk classification date. Across the three risk models (Mayo 2018, IMWG 2020, and AQUILA trial), high-risk patients with SMM had 3.0\u20134.0 times the risk of TTP, 2.1\u20133.5 times the risk of PFS, and 1.7\u20133.2 times the risk of PFS2 versus non-high-risk patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for all comparisons). Similar results were observed when patients with early treatment, early progression, and\/or bone disease were excluded. This study demonstrates that high-risk patients with SMM have worse prognoses than non-high-risk patients, regardless of the criteria used, and highlights a need for early intervention testing.<\/jats:p>","DOI":"10.1038\/s41408-024-01170-z","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T17:13:08Z","timestamp":1733418788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacheeta","family":"Bathija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niodita","family":"Gupta-Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Matt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347\u20139.","journal-title":"N Engl J Med"},{"key":"1170_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.","journal-title":"Blood Cancer J"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069\u201375.","journal-title":"Blood"},{"key":"1170_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood.2021011670","volume":"140","author":"I Vaxman","year":"2022","unstructured":"Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828\u201338.","journal-title":"Blood"},{"key":"1170_CR5","doi-asserted-by":"crossref","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582\u201390.","DOI":"10.1056\/NEJMoa070389"},{"key":"1170_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/hematology.2021000304","volume":"2021","author":"A Visram","year":"2021","unstructured":"Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematol Am Soc Hematol Educ Program. 2021;2021:673\u201381.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1170_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","volume":"46","author":"E Hill","year":"2019","unstructured":"Hill E, Dew A, Kazandjian D. State of the science in smoldering myeloma: should we be treating in the clinic? Semin Oncol. 2019;46:112\u201320.","journal-title":"Semin Oncol"},{"key":"1170_CR8","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.4081\/hr.2020.8951","volume":"12","author":"A Romano","year":"2020","unstructured":"Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How we manage smoldering multiple myeloma. Hematol Rep. 2020;12:8951.","journal-title":"Hematol Rep"},{"key":"1170_CR9","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.4.2024. \u00a9National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 17, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way (2024)."},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"TPS8075","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8075","volume":"40","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Voorhees PM, Goldschmidt H, Baker RI, Shi Y, Rousseau E, et al. Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): randomized, open-label, phase 3 AQUILA study. J Clin Oncol. 2022;40:TPS8075.","journal-title":"J Clin Oncol"},{"key":"1170_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"1170_CR12","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/S2352-3026(21)00335-5","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial S, Rajkumar SV, Mateos MV. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. Lancet Haematol. 2022;9:e162\u20135.","journal-title":"Lancet Haematol"},{"key":"1170_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.","journal-title":"Blood Cancer J"},{"key":"1170_CR14","doi-asserted-by":"publisher","first-page":"e0178420","DOI":"10.1371\/journal.pone.0178420","volume":"12","author":"AP Abernethy","year":"2017","unstructured":"Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, et al. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. PLoS One. 2017;12:e0178420.","journal-title":"PLoS One"},{"key":"1170_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, Nonyane BAS, Ammann EM, Lam A, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95:1486\u201394.","journal-title":"Am J Hematol"},{"key":"1170_CR16","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1002\/cncr.32383","volume":"125","author":"S Khozin","year":"2019","unstructured":"Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, et al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 2019;125:4019\u201332.","journal-title":"Cancer"},{"key":"1170_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30694-w","volume":"13","author":"M Bustoros","year":"2022","unstructured":"Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13:3449.","journal-title":"Nat Commun"},{"key":"1170_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","volume":"7","author":"E Hill","year":"2021","unstructured":"Hill E, Dew A, Morrison C, Yuan C, Stetler-Stevenson M, Landgren O, et al. Assessment of discordance among smoldering multiple myeloma risk models. JAMA Oncol. 2021;7:132\u20134.","journal-title":"JAMA Oncol"},{"key":"1170_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00569-2","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 2021;11:186.","journal-title":"Blood Cancer J"},{"key":"1170_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1182\/hematology.2022000355","volume":"2022","author":"S Thorsteinsdottir","year":"2022","unstructured":"Thorsteinsdottir S, Kristinsson SY. The consultant\u2019s guide to smoldering multiple myeloma. Hematol Am Soc Hematol Educ Program. 2022;2022:551\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1170_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126\u201337.","journal-title":"J Clin Oncol"},{"key":"1170_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127\u201336.","journal-title":"Lancet Oncol"},{"key":"1170_CR23","doi-asserted-by":"crossref","unstructured":"Sandecka V, Popkova T, Stork M, Maisnar V, Minarik J, Jungova A, et al. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies. Blood Cancer J. 2023;13:153.","DOI":"10.1038\/s41408-023-00906-7"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01170-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T18:01:50Z","timestamp":1733421710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01170-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01170-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Vincent Rajkumar is co-editor of <i>Blood Cancer Journal<\/i> but did not participate in the processing or review of this manuscript. Mar\u00eda-Victoria Mateos has served in a consulting or advisory role for Amgen, AbbVie, Celgene, Janssen-Cilag, GlaxoSmithKline, Pfizer, Regeneron, Roche-Genentech, and Takeda, and received honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Genentech, Janssen-Cilag, Sanofi, and Takeda. Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija, Niodita Gupta-Werner, Annette Lam, Robin Carson, Robyn Dennis, Shuchita Kaila, Kathryn Matt, and Joana Duran are employees of Janssen. Sagar Lonial has served in a consulting or advisory role for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen Oncology, Juno Therapeutics, Merck Novartis, and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable as this study was a retrospective, observational study, which leveraged data from the Flatiron Health database. This nationwide oncology practices registry includes deidentified patient data from electronic health records from ~280 cancer clinics in the United States and has been used extensively to generate real-world evidence on various cancers, including multiple myeloma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"215"}}